SIBN Stock News & Analysis | Latest Updates

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.

August 26, 2025Conference

SIBN News

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $22

Forecasting The Future: 6 Analyst Projections For SI-BONE

Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $25 Price Target

Needham Reiterates Buy on SI-BONE, Maintains $24 Price Target

SI-BONE Raises FY2025 Sales Guidance from $193.50M-$195.50M to $193.50M-$197.50M vs $194.25M Est

SI-BONE Q1 EPS $(0.15) Beats $(0.23) Estimate, Sales $47.30M Beat $45.17M Estimate

Expert Outlook: SI-BONE Through The Eyes Of 5 Analysts

Citizens Capital Markets Reiterates Market Outperform on SI-BONE, Maintains $32 Price Target

Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $22

Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $25 Price Target

Needham Maintains Buy on SI-BONE, Raises Price Target to $24

SI-BONE Sees FY2025 Sales $193.500M-$195.500M vs $193.47M Est

SI-BONE Q4 EPS $(0.11) Beats $(0.14) Estimate, Sales $49.00M Beat $47.89M Estimate

Needham Reiterates Buy on SI-BONE, Maintains $19 Price Target

SI-BONE Sees Prelim. FY24 Worldwide Revenue $167.0M-$161.1M

SI-BONE Sees Prelim Q4 Worldwide Revenue $48.8M-$49.0M

The Analyst Verdict: SI-BONE In The Eyes Of 4 Experts

Needham Reiterates Buy on SI-BONE, Maintains $19 Price Target

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Paymen